<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220406054437N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-11-14</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The effect of probiotics on intestinal microbiota</public_title>
      <acronym></acronym>
      <scientific_title>Effect of probiotic supplementation on gut microbiota in patients with food addiction and weight regain after bariatric surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-08-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64936</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study is a Triple-blind Randomized Controlled Clinical Trial. A simple method has been used for randomization. Randomization unit is Individual. Excel software has been used for randomization. Using unique codes as ID numbers, and using random numbers generated by the software, participants were randomly assigned to the equal sample size in the intervention and placebo groups.
 (Description of randomization by Excel software: In the first step, we generated 50 random numbers according to the sample size, in the next step, we obtained the rank of these numbers obtained in the first step, in the third step, we divided these numbers by 25, in the fourth step, the numbers that fell between zero and one were in the intervention group and the rest in the placebo group)
  The central service method was used for allocation concealment. A person outside the research team allocated unique codes A and B to the supplements, none of the research team members knew which code belonged to the intervention or placebo group, Blinding description: Study participants, main study researchers, intervention and treatment partners, data collectors, and data analyzers were blinded in this study, and someone outside the study was used for randomization and labeling of probiotic and placebo supplements. The list of random numbers was generated by a statistics professor. It was delivered confidentially to the research team of Tachgen Zist company in Excel form. An unknown person from the research team of Tachgen Zist company was chosen by the company manager as the person responsible for blinding the supplements. Probiotic and placebo supplements were given to the research team in a completely similar shape with Numeric and A/B codes. none of the research team members knew which code belonged to the intervention or placebo group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Food addiction, Weight regain after bariatric surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  Participants take 2 Multi-strain probiotic capsules daily (after breakfast and after lunch) for 12 weeks. All individuals are given a hypocaloric (-300 to 500 kcal/day), high-protein (25% of energy) diet based on basal metabolism rate (using indirect calorimetry) and level of physical activity (using metabolic equivalents task: MET). For all individuals, ten sessions (Once a week individually) of Cognitive behavioral therapy (CBT) intervention will be performed online based on the Michael Frey protocol.  Each probiotic capsule contains Lactobacillus acidophilus (1.8 × 109 CFU / capsule), Bifidobacterium bifidum (1.8 × 109 CFU / capsule), Bifidobacterium lactis (1.8 × 109 CFU / capsule), Bifidobacterium longul / C, 1.8 (1 × 109 CFU / capsule), Lactobacillus reuteri (1 × 109 CFU / capsule), magnesium stearate and maltodextrin,  produced by Tach Gene Zist Company. Intervention 2: Control group: Participants in the control group take two placebo capsules (after breakfast and lunch) daily for 12 weeks, containing 300 mg of starch. The capsules are completely similar in shape, size and color to the intervention capsules and are produced by Tach Gene Zist Company. All individuals are given a hypocaloric (-300 to 500 kcal/day), high-protein (25% of energy) diet based on basal metabolism rate (using indirect calorimetry) and level of physical activity (using metabolic equivalents task: MET). For all individuals, ten sessions (Once a week individually) of Cognitive behavioral therapy (CBT) intervention will be performed online based on the Michael Frey protocol.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Other studies are supposed to be done on these participans in the continuation of this proposal, Therefore, no decision has been made regarding the publication of the data.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Atoosa Saidpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 7, West Arghavan Ave., Farahzadi Blvd., Qods Town</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1981619573</zip>
        <telephone>+98 21 2207 7425</telephone>
        <email>Atoosa.Saidpour@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Atoosa Saidpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 7, West Arghavan Ave., Farahzadi Blvd., Qods Town</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1981619573</zip>
        <telephone>+98 21 2207 7425</telephone>
        <email>Atoosa.Saidpour@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>At least 18 months have passed since the date of bariatric surgery and having weight regain of at least 10% of the lowest weight gained
Confirmation of food addiction with yale food addiction scale (YFAS)
Being in the age range of 18-50 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy, lactation, menopause
professional athlete
Use of any type of antibiotic in the last three weeks
Using any type of probiotic product or protein supplement in the last month
Having liver diseases (other than fatty liver), kidney, cancer and thyroid diseases
Use of weight loss and appetite suppressants</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  Participants take 2 Multi-strain probiotic capsules daily (after breakfast and after lunch) for 12 weeks. All individuals are given a hypocaloric (-300 to 500 kcal/day), high-protein (25% of energy) diet based on basal metabolism rate (using indirect calorimetry) and level of physical activity (using metabolic equivalents task: MET). For all individuals, ten sessions (Once a week individually) of Cognitive behavioral therapy (CBT) intervention will be performed online based on the Michael Frey protocol.  Each probiotic capsule contains Lactobacillus acidophilus (1.8 × 109 CFU / capsule), Bifidobacterium bifidum (1.8 × 109 CFU / capsule), Bifidobacterium lactis (1.8 × 109 CFU / capsule), Bifidobacterium longul / C, 1.8 (1 × 109 CFU / capsule), Lactobacillus reuteri (1 × 109 CFU / capsule), magnesium stearate and maltodextrin,  produced by Tach Gene Zist Company.</i_keyword>
      <i_keyword>Control group: Participants in the control group take two placebo capsules (after breakfast and lunch) daily for 12 weeks, containing 300 mg of starch. The capsules are completely similar in shape, size and color to the intervention capsules and are produced by Tach Gene Zist Company. All individuals are given a hypocaloric (-300 to 500 kcal/day), high-protein (25% of energy) diet based on basal metabolism rate (using indirect calorimetry) and level of physical activity (using metabolic equivalents task: MET). For all individuals, ten sessions (Once a week individually) of Cognitive behavioral therapy (CBT) intervention will be performed online based on the Michael Frey protocol.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bacteroides Abundance in the stool sample. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Polymerase chain reaction (PCR) in stool samples.</prim_outcome>
      <prim_outcome>Lactobacillus Abundance in the stool sample. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Polymerase chain reaction (PCR) in stool samples.</prim_outcome>
      <prim_outcome>Bifidobacterium Abundance in the stool sample. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Polymerase chain reaction (PCR) in stool samples.</prim_outcome>
      <prim_outcome>Megamonas Abundance in the stool sample. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Polymerase chain reaction (PCR) in stool samples.</prim_outcome>
      <prim_outcome>Eubacterium Abundance in the stool sample. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Polymerase chain reaction (PCR) in stool samples.</prim_outcome>
      <prim_outcome>Akkermansia Abundance in the stool sample. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Polymerase chain reaction (PCR) in stool samples.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-03-14</approval_date>
        <contact_name>Ethics committee of national nutrition and food thechnology research institute</contact_name>
        <contact_address>No. 7, West Arghavan Ave., Farahzadi Blvd., Qods Town Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
